Last reviewed · How we verify

SRP + Injectable Platelet-Rich Fibrin

University of Belgrade · FDA-approved active Small molecule

SRP + Injectable Platelet-Rich Fibrin is a Regenerative medicine / Periodontal therapy Small molecule drug developed by University of Belgrade. It is currently FDA-approved for Chronic periodontitis with periodontal bone loss, Periodontal defects requiring tissue regeneration. Also known as: SRP + i-PRF.

SRP (Scaling and Root Planing) combined with Injectable Platelet-Rich Fibrin promotes periodontal tissue regeneration and healing by delivering concentrated growth factors and platelets to diseased periodontal sites.

SRP (Scaling and Root Planing) combined with Injectable Platelet-Rich Fibrin promotes periodontal tissue regeneration and healing by delivering concentrated growth factors and platelets to diseased periodontal sites. Used for Chronic periodontitis with periodontal bone loss, Periodontal defects requiring tissue regeneration.

At a glance

Generic nameSRP + Injectable Platelet-Rich Fibrin
Also known asSRP + i-PRF
SponsorUniversity of Belgrade
Drug classRegenerative medicine / Periodontal therapy
ModalitySmall molecule
Therapeutic areaDentistry / Periodontics
PhaseFDA-approved

Mechanism of action

Scaling and root planing mechanically removes bacterial biofilm and calculus from tooth surfaces and root canals. Injectable Platelet-Rich Fibrin (PRF) is an autologous biomaterial derived from the patient's own blood that concentrates platelets, leukocytes, and fibrin, releasing growth factors (PDGF, VEGF, TGF-β) that stimulate tissue regeneration, angiogenesis, and bone formation in the periodontal defect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SRP + Injectable Platelet-Rich Fibrin

What is SRP + Injectable Platelet-Rich Fibrin?

SRP + Injectable Platelet-Rich Fibrin is a Regenerative medicine / Periodontal therapy drug developed by University of Belgrade, indicated for Chronic periodontitis with periodontal bone loss, Periodontal defects requiring tissue regeneration.

How does SRP + Injectable Platelet-Rich Fibrin work?

SRP (Scaling and Root Planing) combined with Injectable Platelet-Rich Fibrin promotes periodontal tissue regeneration and healing by delivering concentrated growth factors and platelets to diseased periodontal sites.

What is SRP + Injectable Platelet-Rich Fibrin used for?

SRP + Injectable Platelet-Rich Fibrin is indicated for Chronic periodontitis with periodontal bone loss, Periodontal defects requiring tissue regeneration.

Who makes SRP + Injectable Platelet-Rich Fibrin?

SRP + Injectable Platelet-Rich Fibrin is developed and marketed by University of Belgrade (see full University of Belgrade pipeline at /company/university-of-belgrade).

Is SRP + Injectable Platelet-Rich Fibrin also known as anything else?

SRP + Injectable Platelet-Rich Fibrin is also known as SRP + i-PRF.

What drug class is SRP + Injectable Platelet-Rich Fibrin in?

SRP + Injectable Platelet-Rich Fibrin belongs to the Regenerative medicine / Periodontal therapy class. See all Regenerative medicine / Periodontal therapy drugs at /class/regenerative-medicine-periodontal-therapy.

What development phase is SRP + Injectable Platelet-Rich Fibrin in?

SRP + Injectable Platelet-Rich Fibrin is FDA-approved (marketed).

What are the side effects of SRP + Injectable Platelet-Rich Fibrin?

Common side effects of SRP + Injectable Platelet-Rich Fibrin include Infection at injection site, Mild inflammation, Temporary discomfort.

Related